# Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen

> **NCT01267734** · PHASE4 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 3750 (estimated)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DEVICE:** Everolimus-eluting coronary stenting system (EECSS, Promus Element)
- **DEVICE:** Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)
- **DRUG:** Triple anti-platelet therapy (TAT)
- **DRUG:** Double-dose clopidogrel anti-platelet therapy (DDAT)

## Key facts

- **NCT ID:** NCT01267734
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-06
- **Primary completion:** 2011-12
- **Final completion:** 2015-06
- **Target enrollment:** 3750 (ESTIMATED)
- **Last updated:** 2013-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01267734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01267734, "Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01267734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*